International Clinical Trials
Australia
Agent(s): teriflunomide
Treatment mode of action: Immune modulator (reduces immune system over activity)
Study Description/Purpose: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effectiveness and safety of two doses of teriflunomide versus placebo in people with relapsing forms of MS.
Institution(s): Multiple, worldwide
Type of MS: Relapsing
Number of Subjects: 1110
Funding: sanofi-aventis
Enrollment Information: http://www.mstrials.org.au/find-a-ms-trial/
Belarus
Agent(s): teriflunomide
Treatment mode of action: Immune modulator (reduces immune system over activity)
Study Description/Purpose: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effectiveness and safety of two doses of teriflunomide versus placebo in people with relapsing forms of MS.
Institution(s): Multiple, worldwide
Type of MS: Relapsing
Number of Subjects: 1110
Funding: sanofi-aventis
Enrollment Information: Iryna Alokhina, ia@verumua.com
Belgium
Agent(s): LY2127399 (anti-BAFF human antibody)
Study Description/Purpose: A double-blinded, placebo-controlled study to determine safety and effectiveness in people with MS.
Treatment mode of action: To affect immune function.
Institution(s): Multicenter, worldwide
Type of MS: RR
Number of Subjects: 245
Funding: Eli Lilly and Company
Enrollment Information: Please call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 and reference NCT00882999; or visit website.
Canada
Agent: Tysabri® (natalizumab)
Treatment mode of action: To affect immune function
Study Description/Purpose: Tysabri Global Observational Program in Safety (TYGRIS), to obtain long-term safety data in multiple sclerosis
Treatment mode of action: To affect immune function
Institution(s): Multiple, United States and Canada
Type of MS: Relapsing forms
Number of Subjects: 2500
Funding: Biogen Idec
Enrollment Information: neurologyclinicaltrials@biogenidec.com
Agent: Lipitor® (atorvastatin, a cholesterol-lowering drug)
Treatment Mode of Action: To affect immune function
Study Description/Purpose: A randomized, double-blind, placebo-controlled, multicenter study to evaluate the effectiveness and safety in patients at high risk for MS
Institution(s): Montreal Neurological Institute, and others in the United States and Canada
Type of MS: Clinically Isolated Syndrome (CIS, a single, isolated neurologic event suggesting loss of nerve-insulating myelin)
Number of Subjects: 152
Funding: DAIT/NIAID
Enrollment Information: Natasha Roberts, 514-398-6052
Agent(s): LY2127399 (anti-BAFF human antibody)
Study Description/Purpose: A double-blinded, placebo-controlled study to determine safety and effectiveness in people with MS.
Treatment mode of action: To affect immune function.
Institution(s): Multicenter, worldwide
Type of MS: RR
Number of Subjects: 245
Funding: Eli Lilly and Company
Enrollment Information: Please call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 and reference NCT00882999; or visit website.
Czech Republic
Agent(s): LY2127399 (anti-BAFF human antibody)
Study Description/Purpose: A double-blinded, placebo-controlled study to determine safety and effectiveness in people with MS.
Treatment mode of action: To affect immune function.
Institution(s): Multicenter, worldwide
Type of MS: RR
Number of Subjects: 245
Funding: Eli Lilly and Company
Enrollment Information: Please call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 and reference NCT00882999; or visit website.
Finland
Agent(s): LY2127399 (anti-BAFF human antibody)
Study Description/Purpose: A double-blinded, placebo-controlled study to determine safety and effectiveness in people with MS.
Treatment mode of action: To affect immune function.
Institution(s): Multicenter, worldwide
Type of MS: RR
Number of Subjects: 245
Funding: Eli Lilly and Company
Enrollment Information: Please call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 and reference NCT00882999; or visit website.
France
Agent: 3-4 diaminopyridine
Treatment Mode of Action: To improve fatigue
Study Description/Purpose: Double-blind, placebo controlled study to determine safety and effectiveness
Institution(s): CHU de Rennes, FRANCE
Type of MS: All types
Number of Subjects: 60
Funding: French Health Ministry
Enrollment Information: gilles.edan@chu-rennes.fr
Agent: Cyclophosphamide vs. methylprednisolone
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Double-blind, randomized study to determine effectiveness in people with recent secondary-progressive MS
Institution(s): Pellegrin Hospital and others, France
Type of MS: SP
Number of Subjects: 360
Funding: French Health Ministry
Enrollment Information: Bruno Brochet, MD, bruno.brochet@chu-bordeaux.fr
Agent(s): LY2127399 (anti-BAFF human antibody)
Study Description/Purpose: A double-blinded, placebo-controlled study to determine safety and effectiveness in people with MS.
Treatment mode of action: To affect immune function.
Institution(s): Multicenter, worldwide
Type of MS: RR
Number of Subjects: 245
Funding: Eli Lilly and Company
Enrollment Information: Please call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 and reference NCT00882999; or visit website.
Agent(s): PI-2302, co-polymer
Treatment Mode of Action: To affect immune function
Study Description/Purpose: A randomized, double-blind, placebo-controlled study to determine safety, tolerability, and pharmacokinetics of multiple doses
Institution(s): Multiple, France
Type of MS: SP
Number of Subjects: up to 53
Funding: Peptimmune
Enrollment Information: andre.paquin@biotrial.com, meriam.djemai@biotrial.com, 33-02-9959-9191
Agent: Progesterone and estradiol (sex hormones)
Treatment Mode of Action: To affect immune function
Study Description/Purpose: A double-blind study to determine if treatment with progesterone and estradiol can prevent post-partum relapses in women with multiple sclerosis.
Institution(s): Hospices Civils de Lyon, and others, Europe
Type of MS: Relapsing MS
Number of Subjects: 300
Funding: French Ministry of Health
Enrollment Information: Juliana Achiti, MD, popartmus@edmus.org
Agent(s): teriflunomide
Treatment mode of action: Immune modulator (reduces immune system over activity)
Study Description/Purpose: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effectiveness and safety of two doses of teriflunomide versus placebo in people with relapsing forms of MS.
Institution(s): Multiple, worldwide
Type of MS: Relapsing
Number of Subjects: 1110
Funding: sanofi-aventis
Enrollment Information: Helene.merle@chu-lyon.fr
Germany
Agent(s): LY2127399 (anti-BAFF human antibody)
Study Description/Purpose: A double-blinded, placebo-controlled study to determine safety and effectiveness in people with MS.
Treatment mode of action: To affect immune function.
Institution(s): Multicenter, worldwide
Type of MS: RR
Number of Subjects: 245
Funding: Eli Lilly and Company
Enrollment Information: Please call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 and reference NCT00882999; or visit website.
Hungary
Agent(s): LY2127399 (anti-BAFF human antibody)
Study Description/Purpose: A double-blinded, placebo-controlled study to determine safety and effectiveness in people with MS.
Treatment mode of action: To affect immune function.
Institution(s): Multicenter, worldwide
Type of MS: RR
Number of Subjects: 245
Funding: Eli Lilly and Company
Enrollment Information: Please call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 and reference NCT00882999; or visit website.
Israel
Agent(s): LY2127399 (anti-BAFF human antibody)
Study Description/Purpose: A double-blinded, placebo-controlled study to determine safety and effectiveness in people with MS.
Treatment mode of action: To affect immune function.
Institution(s): Multicenter, worldwide
Type of MS: RR
Number of Subjects: 245
Funding: Eli Lilly and Company
Enrollment Information: Please call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 and reference NCT00882999; or visit website.
Agent: T cell vaccination
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Double-blind study to determine safety and effectiveness
Institution(s): Sheba Medical Center, Tel-Hashomer, Israel
Type of MS: At risk for MS
Number of Subjects: 76
Funding: Horowitz Foundation
Enrollment Information: Dr. Anat Achiron, 3-530-932
Italy
Agent: Rebif® + estroprogestins
Treatment Mode of Action: To affect immune function
Study description/purpose: A randomized, single-blinded, study to test safety and effectiveness
Institution(s): University of Rome “La Sapienza,” and others, Italy
Type of MS: RR
Number of subjects: 180
Funding: University of Rome “La Sapienza”
Enrollment Information: fabiana.marineli@uniroma1.it
Agent: Progesterone and estradiol (sex hormones)
Treatment Mode of Action: To affect immune function
Study Description/Purpose: A double-blind study to determine if treatment with progesterone and estradiol can prevent post-partum relapses in women with multiple sclerosis.
Institution(s): Hospices Civils de Lyon and others, Europe
Type of MS: Relapsing MS
Number of Subjects: 300
Funding: French Ministry of Health
Enrollment Information: Juliana Achiti, MD, popartmus@edmus.org
Mexico
Agent(s): teriflunomide
Treatment mode of action: Immune modulator (reduces immune system over activity)
Study Description/Purpose: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effectiveness and safety of two doses of teriflunomide versus placebo in people with relapsing forms of MS.
Institution(s): Multiple, worldwide
Type of MS: Relapsing
Number of Subjects: 1110
Funding: sanofi-aventis
Enrollment Information: Dr. Jose Manuel Aleman Pedroza, jaleman@uag.mx, Hospital Dr. Angel Leaño; Dr. Ildefonso Rodríguez Leyva, neurologiahc@prodigy.net.mx, Hospital Ignacio Morones Prieto; Dr. Arturo Violante Villanueva; aviolantev@yahoo.com.mx, Instituto Nacional de Neurología y Neurocirugía, Clinica de Esclerosis Multiple; Dr. Minerva López Ruíz; lopez69ruiz@hotmail.com, Hospital General de México; Dr. Juan Fernando Gongora Rivera, fernando.gongora@hotmail.com, Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
Morocco
Agent(s): teriflunomide
Treatment mode of action: Immune modulator (reduces immune system over activity)
Study Description/Purpose: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effectiveness and safety of two doses of teriflunomide versus placebo in people with relapsing forms of MS.
Institution(s): Mu ltiple, worldwide
Type of MS: Relapsing
Number of Subjects: 1110
Funding: sanofi-aventis
Enrollment Information: Pr Ouhabi ; ouhabiha@hotmail.com
Poland
Agent(s): LY2127399 (anti-BAFF human antibody)
Study Description/Purpose: A double-blinded, placebo-controlled study to determine safety and effectiveness in people with MS.
Treatment mode of action: To affect immune function.
Institution(s): Multicenter, worldwide
Type of MS: RR
Number of Subjects: 245
Funding: Eli Lilly and Company
Enrollment Information: Please call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 and reference NCT00882999; or visit website.
Romania
Agent(s): LY2127399 (anti-BAFF human antibody)
Study Description/Purpose: A double-blinded, placebo-controlled study to determine safety and effectiveness in people with MS.
Treatment mode of action: To affect immune function.
Institution(s): Multicenter, worldwide
Type of MS: RR
Number of Subjects: 245
Funding: Eli Lilly and Company
Enrollment Information: Please call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 and reference NCT00882999; or visit website.
Russian Federation
Agent(s): LY2127399 (anti-BAFF human antibody)
Study Description/Purpose: A double-blinded, placebo-controlled study to determine safety and effectiveness in people with MS.
Treatment mode of action: To affect immune function.
Institution(s): Multicenter, worldwide
Type of MS: RR
Number of Subjects: 245
Funding: Eli Lilly and Company
Enrollment Information: Please call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 and reference NCT00882999; or visit website.
Serbia
Agent(s): LY2127399 (anti-BAFF human antibody)
Study Description/Purpose: A double-blinded, placebo-controlled study to determine safety and effectiveness in people with MS.
Treatment mode of action: To affect immune function.
Institution(s): Multicenter, worldwide
Type of MS: RR
Number of Subjects: 245
Funding: Eli Lilly and Company
Enrollment Information: Please call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 and reference NCT00882999; or visit website.
Slovakia
Agent(s): LY2127399 (anti-BAFF human antibody)
Study Description/Purpose: A double-blinded, placebo-controlled study to determine safety and effectiveness in people with MS.
Treatment mode of action: To affect immune function.
Institution(s): Multicenter, worldwide
Type of MS: RR
Number of Subjects: 245
Funding: Eli Lilly and Company
Enrollment Information: Please call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 and reference NCT00882999; or visit website.
Switzerland
Agent(s): LY2127399 (anti-BAFF human antibody)
Study Description/Purpose: A double-blinded, placebo-controlled study to determine safety and effectiveness in people with MS.
Treatment mode of action: To affect immune function.
Institution(s): Multicenter, worldwide
Type of MS: RR
Number of Subjects: 245
Funding: Eli Lilly and Company
Enrollment Information: Please call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 and reference NCT00882999; or visit website.
Thailand
Agent(s): teriflunomide
Treatment mode of action: Immune modulator (reduces immune system over activity)
Study Description/Purpose: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effectiveness and safety of two doses of teriflunomide versus placebo in people with relapsing forms of MS.
Institution(s): Multiple, worldwide
Type of MS: Relapsing
Number of Subjects: 1110
Funding: sanofi-aventis
Enrollment Information: JT.Tibung@sanofi-aventis.com
Tunisia
Agent(s): teriflunomide
Treatment mode of action: Immune modulator (reduces immune system over activity)
Study Description/Purpose: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effectiveness and safety of two doses of teriflunomide versus placebo in people with relapsing forms of MS.
Institution(s): Multiple, worldwide
Type of MS: Relapsing
Number of Subjects: 1110
Funding: sanofi-aventis
Enrollment Information: Riadh Gouider; rg@gnet.tn
Turkey
Agent(s): teriflunomide
Treatment mode of action: Immune modulator (reduces immune system over activity)
Study Description/Purpose: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effectiveness and safety of two doses of teriflunomide versus placebo in people with relapsing forms of MS.
Institution(s): Multiple, worldwide
Type of MS: Relapsing
Number of Subjects: 1110
Funding: sanofi-aventis
Enrollment Information: Prof. Dr. Gülşen F.Akman Demir; akmandem@istanbul.edu.tr
Ukraine
Agent(s): LY2127399 (anti-BAFF human antibody)
Study Description/Purpose: A double-blinded, placebo-controlled study to determine safety and effectiveness in people with MS.
Treatment mode of action: To affect immune function.
Institution(s): Multicenter, worldwide
Type of MS: RR
Number of Subjects: 245
Funding: Eli Lilly and Company
Enrollment Information: Please call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 and reference NCT00882999; or visit website.
Agent(s): teriflunomide
Treatment mode of action: Immune modulator (reduces immune system over activity)
Study Description/Purpose: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effectiveness and safety of two doses of teriflunomide versus placebo in people with relapsing forms of MS.
Institution(s): Multiple, worldwide
Type of MS: Relapsing
Number of Subjects: 1110
Funding: sanofi-aventis
Enrollment Information: Iryna Alokhina, ia@verumua.com
—
Rebif is a registered trademark of Ares Trading S.A.
Tysabri is a registered trademark of Elan Pharmaceuticals, Inc.
Lipitor is a registered trademark of Pfizer.